MAPT and supranuclear palsy, progressive, 1: Many imaging studies in humans have reported possible PSP biomarkers, including brainstem atrophy (plus MRI index, Quattrone et al., 2018), brain pathological changes in both diffusion-weighted and tensor MRI, a reduction in cerebral [18F] fluorodeoxyglucose uptake, striatal dopamine imaging abnormalities, and neurofibrillary tangles of tau pathology on PET (Passamonti et al., 2017).